First-in-human results of an in-body tissue architecture-induced tissue-engineered vascular graft "Biotube" for application in distal bypass for chronic limb-threatening ischemia

Ryuji Higashita; Manami Miyazaki; Masaya Oi; Noboru Ishikawa

doi:10.1016/j.jvscit.2022.07.007

First-in-human results of an in-body tissue architecture-induced tissue-engineered vascular graft "Biotube" for application in distal bypass for chronic limb-threatening ischemia

J Vasc Surg Cases Innov Tech. 2022 Jul 31;8(3):488-493. doi: 10.1016/j.jvscit.2022.07.007. eCollection 2022 Sep.

Authors

Ryuji Higashita¹, Manami Miyazaki¹, Masaya Oi¹, Noboru Ishikawa²

Affiliations

¹ Department of Cardiovascular Surgery, Yokohama General Hospital, Yokohama, Japan.
² Department of Cardiovascular Surgery, Sanai Memorial Hospital, Chiba, Japan.

Abstract

Small-diameter vascular substitutes remain necessary, especially in the absence of an available autologous vein. Using a completely autologous approach termed "in-body tissue architecture," a small-diameter, long, tissue-engineered vascular graft, a "Biotube," was developed. A below-the-knee distal bypass using the Biotube as a composite with expanded polytetrafluoroethylene grafts was performed to treat a patient with chronic limb-threatening ischemia without a venous graft available. The wound on the foot had completely healed 3 months after the bypass surgery, and limb salvage and walking without claudication were achieved. At the 1-year postoperative follow-up examination, duplex ultrasound scans demonstrated graft patency without thrombus or stenosis.

Keywords: Chronic limb-threatening ischemia; In-body tissue architecture; Peripheral artery bypass surgery; Small diameter vascular conduit; Tissue-engineered vascular graft.

Publication types

Case Reports